We validate GLUT1 as an effective anti-cancer target by demonstrating that BAY-876 blocks GLUT1-dependent glycolytic metabolism in ovarian cancer, resulting in potent inhibition of tumor cell growth in vitro and in vivo. The gene discussed is SLC2A1; the disease is ovarian carcinoma.